Ivermectin and COVID-19: An Honest Record of the Controversy

Ivermectin Covid Controversy — scientific infographic poster

Between 2020 and 2023, a Nobel-honored antiparasitic drug became the most argued-about medicine on Earth. Families split over it. Doctors lost jobs over it. Regulators tweeted about horses, and a Nobel laureate — the discoverer himself — publicly took the side officialdom rejected. Most coverage of the ivermectin–COVID story was written to win an argument, in one direction or the other. This page is written to record it: what was claimed, what was tested, what was fraudulent, what was null, what each side got right and wrong, and where honest uncertainty briefly lived and what closed it. Claims are documented as claims, evidence tiers are labeled, harms sit beside hopes, and inclusion is never endorsement.

The bottom line, stated up front so nothing below feels like a lawyer's build-up: the rigorous randomized trials, run at standard and elevated doses, found no clinically meaningful benefit of ivermectin for treating COVID-19 — and the early evidence that suggested otherwise was contaminated by fraud, confounding, and a parasite-related artifact that is itself one of the most instructive scientific detours of the pandemic. How a genuinely great drug ended up in this position is a story worth telling properly.

Table of Contents

  1. Why This Page Exists
  2. April 2020: The Petri-Dish Spark
  3. The Hope Phase
  4. A Withdrawn Egyptian Preprint and Its Data Problems
  5. The Proponents' Case, Documented
  6. Ōmura's Own Verdict
  7. The Rigorous Trials
  8. Cochrane and the Regulators
  9. The Strongyloides Confounder
  10. What Each Side Got Right — and Wrong
  11. Where Honest Uncertainty Remains
  12. What the Record Shows in Practice
  13. Key Research Papers
  14. Connections
  15. Featured Videos

1. Why This Page Exists

This site keeps a hub honoring Satoshi Ōmura because ivermectin's record against parasitic disease is one of medicine's monuments. That is precisely why the COVID chapter cannot be skipped or sanitized: a page that celebrated the wonder drug and whispered past its most famous controversy would teach readers to distrust everything else on it. And there is a second reason. The ivermectin–COVID episode is the best modern case study in how medical evidence works — how lab findings mislead, how fraud propagates through meta-analyses, how honest signals arise from confounding, and how large randomized trials eventually settle what shouting could not. A reader who follows this one story attentively will come out better equipped to judge the next contested remedy, whatever it is.

Some context for why the hypothesis was never crazy: ivermectin had shown laboratory activity against several RNA viruses (dengue, Zika, and others) in the 2010s, via a proposed mechanism — blocking a cellular import shuttle some viruses borrow — unrelated to its parasite-killing chloride-channel action (see the pharmacology article). Drug repurposing is real science; this same drug's move from cattle to river blindness, and later to rosacea, was repurposing. The question was never whether the idea deserved testing. It was what the tests would show, and what everyone would do while waiting.

2. April 2020: The Petri-Dish Spark

On April 3, 2020 — weeks into global lockdowns, with no proven treatments — Leon Caly, Kylie Wagstaff, and colleagues at Monash University and the Doherty Institute in Australia published a short paper in Antiviral Research: in monkey-kidney cells in a dish, ivermectin at 5 micromolar concentration reduced SARS-CoV-2 viral RNA roughly 5,000-fold in 48 hours. The paper was real, competent, and instantly world-famous.

The problem was visible on day one to anyone who read the concentration and did division. Five micromolar is enormous for this drug: the peak blood level from a standard 200 µg/kg human dose is on the order of fifty to a hundred times lower than the concentration used in the dish. Pharmacologists ran the models within weeks (Schmith and colleagues, cited below): the concentration that halved viral growth in the dish (2 µM) was more than 35 times the peak blood level after the approved 200 µg/kg dose taken on an empty stomach, and even at ten times the approved dose — the ceiling formally tested for safety — the predicted lung concentration was only about 0.82 µM, still far short of the dish. Plenty of substances kill viruses in glassware at high concentration — the joke in pharmacology is that so does a flamethrower; the whole game is achieving the effect at levels a living human can sustain. So the honest April 2020 summary was: a legitimate lead with a known, serious dosing gap — worth trials, unlikely on the numbers.

Two clarifications apply to both camps. To skeptics: "in vitro concentrations were unachievable" is an argument for skepticism, not proof of futility — tissue accumulation and secondary mechanisms (ivermectin does concentrate in lung tissue and has plausible anti-inflammatory actions) meant a modest clinical effect could not be excluded from an armchair. That is why running the big trials was right. To proponents: the gap was never answered, only waved at — and when trials at 600 µg/kg for six days later came back null (below), the "just dose higher" version of the hypothesis had been tested on its own terms.

3. The Hope Phase

Through mid-2020, small studies and desperate systems generated real-looking hope. An influential observational report (the "ICON" study, Florida) found lower mortality in ivermectin-treated hospitalized patients; small trials from several countries reported faster viral clearance or symptom relief; and some governments acted — Peru added ivermectin to national guidelines in May 2020 (later removing it), parts of Bolivia and several Indian states distributed it, and in India's Uttar Pradesh it entered home-treatment kits. When case waves later fell in those places, proponents read vindication; when they fell equally in comparable places that never used ivermectin, skeptics read regression and rising immunity. Ecological data of this kind — whole-population before/after comparisons with no controls — sit on the lowest rung of the evidence ladder, and they are labeled accordingly here: suggestive to the hopeful eye, uninterpretable to the careful one, in both directions.

In November 2020, a group of practicing US critical-care physicians placed ivermectin at the center of its I-MASK+ protocol. On December 8, 2020, one of the group's leaders testified before a US Senate committee, calling ivermectin a "miracle drug" whose mountain of data made further placebo-controlled trials almost unethical. The clip traveled the world. Document the claim, label the tier: what stood behind it at that moment was a mixture of in-vitro work, observational series, and small trials of very uneven quality — the exact evidence stratum from which pandemic history's false leads (hydroxychloroquine most recently) had always been built. The group's physicians were real clinicians seeing real dying patients, and their frustration with the treatment vacuum was widely shared.

4. A Withdrawn Egyptian Preprint and Its Data Problems

The single most consequential document of the hope phase was a preprint from a university research group in Egypt, posted November 2020, reporting on roughly 400 patients and claiming, among other things, a 90% reduction in mortality with ivermectin. Because it was large and dramatic, it dominated early meta-analyses, the statistical summaries that pool trials into a single estimate.

In mid-2021 it fell apart, and the way it fell apart matters. A London master's student assigned to appraise the paper noticed plagiarized passages; independent researchers then reported problems in the dataset: blocks of apparently duplicated patient records and deaths whose recorded dates preceded the study. The preprint server withdrew the paper on July 14, 2021; the affair is chronicled in the Nature news feature by Sara Reardon (Nature 2021;596:173-174).

Now watch the contamination propagate. A widely cited meta-analysis by Hill and colleagues, in its January 2021 preprint version, reported a 75% reduction in mortality across six trials of moderate or severe infection (14 of 650 deaths with ivermectin vs 57 of 597 in the control groups), and its pooled results included the Egyptian preprint. The version now on the journal's record (Open Forum Infectious Diseases, 2021) was revised after the preprint's problems came to light: with studies at high risk of bias excluded, ivermectin “did not show a statistically significant effect on survival” (risk ratio 0.90, 95% CI 0.57–1.42). The authors' 2022 reanalysis found that the survival effect “was dependent on largely poor-quality studies” — risk ratio 0.08 in the potentially fraudulent study against 0.96 in the low-risk studies — and the 2021 article was formally retracted in February 2022 (original, retraction, reanalysis). A second 2021 meta-analysis (American Journal of Therapeutics), which reported a 62% mortality reduction (average risk ratio 0.38 across 15 trials) and became the proponents' central citation, likewise included the Egyptian preprint and other studies later flagged. The lesson is stated in a 2021 essay in Nature Medicine by researchers involved in the data checks (cited below): meta-analyses built on summary data are only as sound as their weakest included trial, because pooling cannot detect fabrication — it launders it into a confidence interval.

The fraud does not prove ivermectin fails against COVID; fraud proves nothing except itself. What it explains is why the early evidence looked so strong — and why everything afterward had to rest on trials whose raw data could be trusted.

5. The Proponents' Case, Documented

Per site policy, here is the proponents' case at its strongest, stated as its holders stated it — documented faithfully, labeled as claims:

That is the case as it was made. The rest of this page tests it against what happened when the highest-quality instruments science has — large, blinded, randomized trials — were finally aimed at it.

6. Ōmura's Own Verdict

In March 2021, Ōmura co-authored a long review in the Japanese Journal of Antibiotics — Yagisawa, Foster, Hanaki & Ōmura, "Global trends in clinical studies of ivermectin in COVID-19" (not PubMed-indexed; doi:10.11553/antibiotics.74.1_44) — surveying the observational and early trial data. It concluded that, as of February 27, 2021, meta-analyses of 42 clinical studies showed ivermectin to be effective in treating and preventing COVID-19; it cited the early version of Hill and colleagues' meta-analysis among those affirming effectiveness; it asked regulators for “legitimate and compelling explanations” for not allowing clinical use; and it stated that the original manufacturer's February 2021 statement against ivermectin for COVID-19 did not provide any scientific basis for its claims. His position is documented here as he stated it: the discoverer of the avermectins, at 85, publicly argued his molecule could help against the pandemic and pushed for Japan to test and use it.

Two things distinguish Ōmura's conduct from much of the movement that quoted him. First, he asked for trials, and his institute ran one. Kitasato University mounted CORVETTE-01, a double-blind, placebo-controlled randomized trial of a single 200 µg/kg dose in mild-to-moderate COVID-19. Its result, published in 2023 (Wada et al., cited below), was null: among 221 randomized patients, the median time to a negative PCR test was 14 days with ivermectin and 14 days with placebo (hazard ratio 0.96). Second, when a Japanese drug company — partnering with Kitasato — ran a full phase III trial (IVERMILCO) in 1,030 omicron-era outpatients with mild COVID-19 in Japan and Thailand, at 0.3–0.4 mg/kg once daily for three days, it too reported no efficacy: symptoms first began to improve at about 96 hours (four days) in both the ivermectin and placebo groups (p = 0.61), side effects did not differ between the groups, and the trial included teenagers aged 12 and older (announced September 2022; published as Mikamo et al., J Infect Chemother 2024;30(6):536-543). The laureate's side of the ledger thus contains something rarer than being right: his own institution's trials came back against his hypothesis, and they were published, unspun.

The review's date matters. In March 2021 the evidence base it summarized still included studies that were later withdrawn or flagged for data problems, the Egyptian preprint among them. Its conclusions rested largely on pooled analyses of many small and observational studies — it described the 42-study meta-analysis as having a “1 in 4 trillion” chance of being mistaken — and the trials Ōmura's own side later ran are on this page, counting against the claim.

7. The Rigorous Trials

From 2021 onward, the question finally met instruments worthy of it: large, randomized, mostly placebo-controlled, mostly outpatient trials — testing early treatment, the proponents' own preferred window, several at elevated doses. In chronological order of publication:

Note what this list is not: hospital-only trials that missed the early window (several exist too — also null, including the international REMAP-CAP platform in the critically ill), or low-dose strawmen. The pattern across continents, variants, doses, and durations is as consistent as clinical evidence gets. If a meaningful treatment effect existed at tolerable doses, trials totaling many thousands of randomized patients, several designed around the proponents' own specifications, were positioned to find it. They found, at most, the two-day symptom shading in PRINCIPLE — an effect size in the territory of throat lozenges, not of the mortality revolutions claimed in 2020.

8. Cochrane and the Regulators

The Cochrane review — medicine's standing institution for systematic evidence appraisal, which for this question adopted an unusually strict trials-integrity policy (admitting only randomized trials that had been prospectively registered in a trial registry) — concluded in its 2022 update (Popp et al., below) that for outpatients there is “low- to high-certainty evidence that ivermectin has no beneficial effect”: moderate-certainty evidence of little or no effect on deaths (risk ratio 0.77) and low-certainty evidence of little or no effect on worsening or recovery. For inpatients the evidence was very uncertain, and no eligible trial had tested ivermectin for preventing infection: “No evidence is available on ivermectin to prevent SARS-CoV-2 infection.” The WHO (March 2021 onward) recommended against use outside clinical trials; the European Medicines Agency (EMA) and U.S. National Institutes of Health guidelines panel reached the same destination, the U.S. National Institutes of Health moving from "insufficient evidence" (early 2021) to a recommendation against use (2022) as the large trials read out. The drug's original manufacturer had said in February 2021 that it saw no meaningful evidence of clinical efficacy — a statement proponents discounted because the company was developing its own COVID-19 antiviral, molnupiravir.

Then there is the U.S. Food and Drug Administration (FDA), whose August 2021 social-media post — "You are not a horse. You are not a cow. Seriously, y'all. Stop it." — became the controversy's most famous sentence. It was aimed at a real event: the 2021 surge in poisonings from veterinary formulations (documented in the safety article). It was also widely read as mockery: it let a WHO-essential human medicine be caricatured as horse paste, including for the patients taking it for parasitic disease. In 2024, settling a lawsuit brought by three physicians, the U.S. Food and Drug Administration agreed to delete the posts while conceding no wrongdoing and maintaining its position on efficacy.

9. The Strongyloides Confounder

One genuinely beautiful piece of science emerged from the wreckage, and it deserves its own section. Researchers noticed a geographic pattern in the trial data: the studies showing ivermectin mortality benefits clustered in regions where strongyloidiasis — the chronic worm infection described in the global-health article — is endemic. Avi Bitterman and colleagues formalized it in a meta-analysis (JAMA Network Open, 2022, below): group the trials by regional strongyloidiasis prevalence, and the apparent survival benefit lives almost entirely in the high-prevalence regions, evaporating in the low-prevalence ones. In numbers: 12 trials with 3,901 patients (trials flagged for suspected fraud or failed randomization were left out). In the 4 trials from high-prevalence regions, deaths fell to about a quarter (risk ratio 0.25, 95% CI 0.09–0.70); in the 8 trials from low-prevalence regions there was no significant change (risk ratio 0.84, 95% CI 0.60–1.18). Each 5-point rise in regional prevalence went with a mortality risk ratio about 39% lower.

The proposed mechanism is elegant and grim. COVID-19's standard treatment for serious cases is dexamethasone, a steroid that suppresses immunity — and immunosuppression is precisely the trigger that converts silent strongyloidiasis into disseminated hyperinfection, which kills. In worm-endemic regions, a COVID patient given dexamethasone with an unrecognized Strongyloides infection faces a real added mortality risk — and ivermectin, the definitive strongyloides drug, removes it. In such a trial, the ivermectin arm genuinely dies less. The drug is genuinely saving lives — by killing worms, not coronavirus.

This reframing respects everyone's data while dissolving the contradiction: early positive trials from endemic regions and null mega-trials from non-endemic ones can both be true. It also matches the one point of clinical guidance on which ivermectin enthusiasts and infectious-disease orthodoxy fully agree: long-standing guidance calls for people from endemic regions who need steroids — for COVID or anything else — to be screened or presumptively treated for strongyloidiasis first. That guidance predates the pandemic and outlives it; our Strongyloides treatment page covers it in practical detail.

10. What Each Side Got Right — and Wrong

The proponents were right that the early-pandemic treatment vacuum was intolerable and that repurposing a cheap, safe generic deserved fast, serious testing; right that prescription-dose safety fears were overblown; right that some of the establishment's conduct — the horse mockery, pharmacies refusing legitimate antiparasitic prescriptions, the occasional pretense that the question was settled before the big trials existed — was contemptuous where it should have been merely correct. And in the strongyloides-endemic corner of the world, their drug really was saving some lives in COVID wards, for reasons nobody on either side initially understood.

The proponents were wrong where it counted most: on the clinical claim. The evidence pyramid exists because sincere clinical impressions and small studies mislead — that is not a slur on anyone's honesty, it is the founding observation of modern medicine. The movement absorbed a fraudulent trial into its certainty, and when the fraud was exposed, mostly did not update; when the null mega-trials arrived, the goalposts moved — dose, timing, formulation, conspiracy — through each of which the higher-dose and early-treatment trials had already driven.

The skeptics were right about the pharmacokinetics from week one, right to demand data integrity (the fraud detections were their unglamorous, decisive contribution), and right about where the randomized controlled trials (RCTs) would land. The skeptics were wrong whenever they let being right curdle into ridicule: "horse dewormer" was a falsehood about one of humanity's most important human medicines; conflating barn-shelf self-poisoning with physician-prescribed use smeared legitimate patients; and the reflexive certainty of mid-2020 — before TOGETHER and ACTIV-6 existed — was faith wearing evidence's clothes, the very thing skepticism exists to prevent. The trials were worth running because the question was open; those who said so at the time, on both sides, were the ones doing science.

11. Where Honest Uncertainty Remains

A trustworthy page must say what is still genuinely unknown, and resist inflating it:

12. What the Record Shows in Practice

Key Research Papers

  1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:104787. — PubMed PMID: 32251768
  2. Reardon S. Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature 2021;596(7871):173-174. — PubMed PMID: 34341573
  3. Hill A, Garratt A, Levi J, Falconer J, Ellis L, McCann K, Pilkington V, Qavi A, Wang J, Wentzel H. Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection. Open Forum Infect Dis 2021;8(11):ofab358. RETRACTED (retraction: Open Forum Infect Dis 2022;9(3):ofac056, PMID 35146053). — PubMed PMID: 34796244
  4. Hill A, Mirchandani M, Pilkington V. Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud. Open Forum Infect Dis 2022;9(2):ofab645. — PubMed PMID: 35071686
  5. Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther 2021;28(4):e434-e460. — PubMed PMID: 34145166
  6. Yagisawa M, Foster PJ, Hanaki H, Ōmura S. Global trends in clinical studies of ivermectin in COVID-19. Jpn J Antibiot 2021;74(1):44-95. — doi:10.11553/antibiotics.74.1_44
  7. Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther 2020;108(4):762-765. — PubMed PMID: 32378737
  8. Lawrence JM, Meyerowitz-Katz G, Heathers JAJ, Brown NJL, Sheldrick KA. The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable. Nat Med 2021;27(11):1853-1854. — PubMed PMID: 34552263
  9. López-Medina E, López P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA 2021;325(14):1426-1435. — PubMed PMID: 33662102
  10. Reis G, Silva EASM, Silva DCM, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19 (TOGETHER). N Engl J Med 2022;386(18):1721-1731. — PubMed PMID: 35353979
  11. Lim SCL, Hor CP, Tay KH, et al. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial. JAMA Intern Med 2022;182(4):426-435. — PubMed PMID: 35179551
  12. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial (ACTIV-6). JAMA 2022;328(16):1595-1603. — PubMed PMID: 36269852
  13. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial (ACTIV-6). JAMA 2023;329(11):888-897. — PubMed PMID: 36807465
  14. Popp M, Reis S, Schießer S, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2022;6(6):CD015017. — PubMed PMID: 35726131
  15. Hayward G, Yu LM, et al. Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes. J Infect 2024;88(4):106130. — PubMed PMID: 38431155
  16. Bitterman A, Pereira Martins C, Cices A, Nadendla MP. Comparison of Trials Using Ivermectin for COVID-19 Between Regions With High and Low Prevalence of Strongyloidiasis: A Meta-analysis. JAMA Netw Open 2022;5(3):e223079. — PubMed PMID: 35311963
  17. Wada T, Hibino M, Aono H, et al. Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial. Front Med (Lausanne) 2023;10:1139046. — PubMed PMID: 37283627
  18. Mikamo H, Takahashi S, Yamagishi Y, et al. Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand. J Infect Chemother 2024;30(6):536-543. — PubMed PMID: 38154616

PubMed Topic Searches

  1. PubMed: Ivermectin COVID-19 RCTs
  2. PubMed: Ivermectin SARS-CoV-2 pharmacokinetics
  3. PubMed: Meta-analysis integrity debates
  4. PubMed: Strongyloides and steroids in COVID
  5. PubMed: Drug-repurposing lessons of COVID-19
  6. PubMed: Detecting fraud in clinical trials

Connections

Back to top